ED
ORCL icon

Exane Derivatives’s Oracle ORCL Stock Holding History

Exane Derivatives’s Portfolio ORCL Stock Details ORCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-703
Closed -$58.2K – 882
2022
Q1 		$58.2K Buy
+703
New +$56.9K 0.02% 555
2021
Q2 		– Sell
-71
Closed -$4.98K – 1075
2021
Q1 		$4.98K Sell
71
-7,387
-99% -$478K ﹤0.01% 620
2020
Q4 		$482K Buy
7,458
+7,423
+21,209% +$442K 0.14% 167
2020
Q3 		$2.09K Hold
35
– – ﹤0.01% 561
2020
Q2 		$1.94K Sell
35
-11,989
-100% -$635K ﹤0.01% 507
2020
Q1 		$581K Buy
12,024
+124
+1% +$6.4K 0.16% 111
2019
Q4 		$651K Buy
+11,900
New +$655K 0.12% 134
2019
Q3 		– Sell
-916
Closed -$52.2K – 684
2019
Q2 		$52.2K Buy
916
+66
+8% +$3.57K 0.01% 388
2019
Q1 		$45.6K Buy
+850
New +$43.3K 0.01% 344
2018
Q4 		– Sell
-2,451
Closed -$127K – 723
2018
Q3 		$127K Sell
2,451
-11,551
-82% -$561K 0.02% 293
2018
Q2 		$614K Buy
14,002
+2,561
+22% +$118K 0.1% 160
2018
Q1 		$512K Buy
11,441
+3,004
+36% +$149K 0.1% 169
2017
Q4 		$399K Buy
+8,437
New +$414K 0.07% 191
2017
Q2 		– Sell
-1
Closed -$45 – 669
2017
Q1 		$45 Sell
1
-5,021
-100% -$209K ﹤0.01% 522
2016
Q4 		$193K Sell
5,022
-2,307
-31% -$90.2K 0.04% 204
2016
Q3 		$288K Sell
7,329
-2,899
-28% -$118K 0.04% 188
2016
Q2 		$419K Buy
10,228
+2,169
+27% +$86.6K 0.07% 146
2016
Q1 		$330K Buy
+8,059
New +$298K 0.04% 164
2015
Q3 		– Sell
-13,823
Closed -$557K – 560
2015
Q2 		$557K Buy
13,823
+11,860
+604% +$514K 0.06% 136
2015
Q1 		$84.7K Buy
+1,963
New +$85.1K 0.01% 280

Other funds holding ORCL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Exane Derivatives's ORCL Position: Q2 2022 in Review

Exane Derivatives sold out of Oracle (ORCL) in Q2 2022, closing a stake of 703 shares — an estimated $58.2K sold.

Exane Derivatives first reported a position in ORCL in Q1 2015 and held it in 20 quarters. The position peaked at $651K in Q4 2019. 2,192 funds tracked by Wall St. Rank hold ORCL as of Q2 2022.

  • Exane Derivatives reported no remaining Oracle position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 703 Oracle shares in Q2 2022, an estimated $58.2K.
  • Exane Derivatives first reported a position in Oracle in Q1 2015 and held it in 20 quarters.
  • Exane Derivatives's Oracle position peaked at $651K in Q4 2019.
  • 2,192 funds tracked by Wall St. Rank held Oracle as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.